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See Article, pages 132–138The gut microbiota is considered as a factor involved in the reg-
ulation of numerous metabolic pathways by impacting different
functions of the host. Among these regulations, the inﬂuence of
gut microbes on energy homeostasis is of particular interest
because it has been suggested to be a driving force in the patho-
genesis of metabolic diseases associated with obesity (such as
insulin resistance, diabetes, cardiovascular disease, and non-alco-
holic fatty liver disease (NAFLD)) [1,2]. Intestinal microbes have
developed a mutualistic relationship with their host and can
inﬂuence physiological systems by modulating gut motility,
intestinal barrier homeostasis, nutrient absorption, fat distribu-
tion, and liver fat accumulation [3,4].
The relationship between changes in gut microbiota and the
development and progression of liver disease has been known
for over ﬁfty years. Endotoxemia and gut-derived toxins are sug-
gested to have causative roles in the onset and progression of liver
inﬂammation and damage in chronic liver diseases [5]. Similar to
the mechanisms underlying metabolic endotoxemia (i.e.,
increased blood lipopolysaccharides (LPS) levels) and inﬂamma-
tion described in our previous work [6], intestinal bacterial over-
growth, gut leakiness and increased endotoxin absorption have all
been associated with hepatic fat accumulation and inﬂammation
(NAFLD and non-alcoholic steatohepatitis (NASH)) in both rodents
and human patients [7–9]. However, the role of speciﬁc bacteria,
metabolites coming from the gut microbiota or both remained to
be demonstrated.
In NAFLD patients changes in tight junction protein expres-
sion and distribution are suggested as critical factors in the
impairment of gut barrier function and subsequent alterations
in gut permeability [10]. As a consequence, metabolic endotoxe-
mia exposes the liver to gut-derived toxins resulting in the
release of numerous pro-inﬂammatory cytokines that ultimately
lead to hepatic injury and ﬁbrosis [11]. However, although previ-
ous studies have shown that the treatment with antibiotics or
loss of endotoxins receptors (Toll-like receptor-(TLR) 4) signiﬁ-
cantly attenuates the development of hepatic steatosis in mice
[12,13], it has also been suggested that other TLRs than TLR4
contributed to the onset of NAFLD [14]. In light of these recentJournal of Hepatology 20
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communities as well as identifying the cross-talks existing
between organs and the gut microbiota related to metabolism
regulation is of the utmost importance.
The present study by Munukka et al. in this issue of the Journal
of Hepatology provides a putative link between the abundance of
one speciﬁc bug, namely Faecalibacterium prausnitzii, hepatic fat
accumulation and adipose tissue inﬂammation. By using proton
magnetic resonance spectroscopy (1H MRS) they classiﬁed their
population comprising of 31 subjects into two distinct groups,
that is high hepatic fat content (>5%, n = 10) and low hepatic
fat content (<5%, n = 21). Munukka et al. also investigated
whether hepatic fat content was associated with body composi-
tion, adipose tissue inﬂammation (by microarray) and speciﬁc
gut microbes (by 16S rRNA hybridization and ﬂow cytometry).
The major limitations of this study rely on the fact that the num-
ber of patients was relatively small and more importantly
because of the use of a targeted approach to investigate the gut
microbiota. But, besides these points, the authors found that a
lower abundance of F. prausnitzii is associated with hepatic fat
accumulation. Moreover, this remained signiﬁcant after adjust-
ment for gender, age and weight, which reinforce a putative link
between this bacterium and host metabolism.
Conversely with previous reports [15], they found that the
abundance of the Bacteroides group was positively correlated
with insulin resistance index (HOMA-IR). When they combined
the data obtained for F. prausnitzii and Bacteroides as a ratio (F.
prausnitzii/Bacteroides), the authors found that the level of several
genes expressed in the subcutaneous adipose depots and related
with inﬂammation were negatively associated with this ratio.
Interestingly, no signiﬁcant differences were found at the level
of several genes involved in lipid metabolism. It is worth noting
that in the present study the authors had access to subcutaneous
adipose tissues which is likely less prone to directly induce an
overﬂow of the liver with fatty acids, and this in comparison with
the visceral adipose-derived fatty acids. Thus, given that in this
study the patients with a higher liver fat accumulation exhibited
more visceral fat accumulation (2-fold more) it is likely that both
type of fat depots contribute to the development of hepatic fat
accumulation via complementary mechanisms, that are directly
or indirectly associated with the gut microbiota. Nevertheless,
in this study Munukka et al. unequivocally found that the14 vol. 61 j 5–6
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increased inﬂammatory tone observed in the subcutaneous adi-
pose tissue was correlated with the presence of F. prausnitzii
and Bacteroides and eventually suggest a link between the gut,
subcutaneous adipose tissue, and liver fat accumulation.
Although this direct link was not shown in the present study,
it has been previously demonstrated that higher abundance of F.
prausnitzii was associated with an improved inﬂammatory status
in obese patients [16]. Moreover, a reduction in a cluster of genes
belonging to F. prausnitziiwas identiﬁed as a discriminant marker
for the prediction of diabetic status in European women [17],
which may support the link with F. prausnitzii observed in the
present study and HOMA-IR. Moreover, rodents studies have
clearly associated the role of F. prausnitzii with intestinal barrier
function [18].
Strikingly, the decreased abundance of several genera includ-
ing Bacteroides (which was decreased in the present study) and F.
prausnitzii has also been found in type 2 diabetic Chinese subjects
[19]. Moreover, Balamurugan et al. found that F. prausnitzii was
increased in obese Indian children compared to the lean controls
[20]. Thus these discrepancies strongly highlight once again that
the speciﬁcity of the population, age, and diets in phenotype and
taxonomy associations have to be taken into account before
drawing any clear conclusions on the role of one speciﬁc bacte-
rium on the onset or the protection against metabolic disorders
associated with fat accumulation.
Growing evidence suggests that cross-talks between gut
microbes and the host are achieved through speciﬁc metabolites
such as for example short chain fatty acids or speciﬁc molecular
patterns of microbial membranes (e.g., LPS) that may contribute
to the activation of TLR’s.
In this study, Munukka et al. found a positive association
between Enterobacteriaceae family (i.e., Gram negative bacteria)
and triglycerides, but they did not ﬁnd any differences in meta-
bolic endotoxemia measured in the peripheral blood of both
groups. Besides the fact that measuring blood LPS is highly tricky,
and may be an important confounding factor here, previous stud-
ies have clearly associated plasma LPS levels with triglycerides
[21].
Thus, in this study, we may not exclude that numerous
parameters may have contributed to the regulation of hepatic
fat accumulation. Is the phenotype starting from the gut barrier
dysfunction and eventually linked with the presence of LPS or
any other molecular patterns of microbial membranes? Is the
higher inﬂammatory tone observed in the adipose tissue directly
or indirectly associated with any modiﬁcation of the gut barrier
function, or changes in the gut microbiome or both? What is
the abundance of other gut bacteria measured by using high-
throughput methods (e.g., sequencing)? All these questions
remain still unanswered, and merit further investigations.Conﬂict of interest
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